Rankings/Joint & Bone/OmegaCo3 (K-7)
Apex Energetics

OmegaCo3 (K-7)

Joint & BoneServing: 1 TbspType: Other Combinations
N+ Score
D
62
Adequacy
35%
45
Completeness
25%
25
Transparency
20%
100
Diversity
20%
100

About This Product

OmegaCo3 (K-7) is a combination supplement categorized under Joint & Bone, featuring 15 ingredients designed to offer broad support. This product holds an N+ Score of 62, earning a 'D' grade, indicating an average tier product according to our analysis. Key ingredients at clinically studied dosages include Eicosapentaenoic Acid (500mg), Docosahexaenoic Acid (350mg), Vitamin B6 (2.5mg), Zinc (5mg), and Molybdenum (40mcg), which research suggests may support various physiological functions. However, ingredients such as Vitamin E, Niacin, and Calcium are present at underdosed levels, potentially limiting their efficacy. The product demonstrates full label transparency, but its ingredient adequacy and formula completeness scores are 45% and 25% respectively. This product may be suitable for individuals seeking a multi-ingredient formula with specific omega-3 fatty acids and certain micronutrients at effective doses.

Strengths

  • +Fully transparent label with individual ingredient amounts disclosed
  • +Broad ingredient diversity exceeding category norms
  • +7 ingredient(s) at clinical dose levels
  • +Rich formula with 15 active ingredients

Weaknesses

  • Missing several expected ingredients for its category

Ingredient Analysis (15 ingredients)

IngredientAmountStatus
Calories45.000 Calorie(s)N/A
Total Fat4.500 Gram(s)N/A
Eicosapentaenoic Acid500.000 mgOptimal
Docosahexaenoic Acid350.000 mgAdequate
Niacin2.500 mgUnder
Vitamin B62.500 mgOptimal
Vitamin E6.000 IUUnder
Calcium20.000 mgUnder
Magnesium10.000 mgUnder
Zinc5.000 mgAdequate
Total Carbohydrates1.000 Gram(s)N/A
Cholesterol30.000 mgN/A
Molybdenum40.000 mcgAdequate
Taurine75.000 mgN/A
Gamma-Linolenic Acid100.000 mgAdequate

Clinical ranges based on NIH ODS Fact Sheets and peer-reviewed research. Status indicates whether the amount meets evidence-based thresholds.